Sarah C Gilbert

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, OX3 7BN, Oxford, UK
    Vaccine 20:1039-45. 2002
  2. ncbi request reprint Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
  3. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
  4. ncbi request reprint Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
  5. pmc Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 19:2269-76. 2011
  6. ncbi request reprint Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
    Arturo Reyes-Sandoval
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Eur J Immunol 38:732-41. 2008
  7. pmc The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment
    Anna L Goodman
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Sci Rep 3:1706. 2013
  8. ncbi request reprint Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers
    Jenni M Vuola
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    J Immunol 174:449-55. 2005
  9. pmc Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine
    Timothy J Powell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS ONE 8:e62778. 2013
  10. ncbi request reprint Effective induction of high-titer antibodies by viral vector vaccines
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Nat Med 14:819-21. 2008

Detail Information

Publications79

  1. ncbi request reprint Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, OX3 7BN, Oxford, UK
    Vaccine 20:1039-45. 2002
    ..This study identifies recombinant replication-defective adenovirus as an alternative to recombinant replication-defective poxviruses as boosting agents for the induction of strong protective CD8(+) T cell responses...
  2. ncbi request reprint Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
    ..In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials...
  3. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
    ....
  4. ncbi request reprint Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
    ..These viral vectors now provide a major option for inclusion in a high efficacy multi-stage malaria vaccine that should achieve deployable levels of efficacy in endemic settings...
  5. pmc Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 19:2269-76. 2011
    ..Further studies are required to assess whether this strategy can achieve protective efficacy against blood-stage malaria infection...
  6. ncbi request reprint Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
    Arturo Reyes-Sandoval
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Eur J Immunol 38:732-41. 2008
    ..Our data suggest that T(EM) cells are important as a first line of defense against fast-replicating pathogens such as murine Plasmodium and demonstrate the potential of replication-defective SAd as future malaria vaccines for humans...
  7. pmc The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment
    Anna L Goodman
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Sci Rep 3:1706. 2013
    ..An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum...
  8. ncbi request reprint Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers
    Jenni M Vuola
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    J Immunol 174:449-55. 2005
    ..This difference may be of importance for the protective efficacy of these vaccination approaches against various diseases...
  9. pmc Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine
    Timothy J Powell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS ONE 8:e62778. 2013
    ..BCL2 expression was lower in vaccinated volunteers. These data indicate that antigen specific T cells are a useful additional measure for use in human vaccination or immunization studies...
  10. ncbi request reprint Effective induction of high-titer antibodies by viral vector vaccines
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Nat Med 14:819-21. 2008
    ..Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro...
  11. pmc Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1
    Sumi Biswas
    The Jenner Institute, University of Oxford, Oxford, Oxfordshire, United Kingdom
    PLoS ONE 6:e20977. 2011
    ..Here we describe the pre-clinical development and optimization of recombinant human and simian adenoviral (AdHu5 and ChAd63) and orthopoxviral (MVA) vectors encoding transgene inserts for Plasmodium falciparum AMA1 (PfAMA1)...
  12. ncbi request reprint A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS
    Susanna J Dunachie
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Vaccine 24:2850-9. 2006
    ..Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months...
  13. pmc Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom
    Infect Immun 78:145-53. 2010
    ....
  14. ncbi request reprint Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity
    Claire L Hutchings
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 175:599-606. 2005
    ....
  15. pmc Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Cell Host Microbe 5:95-105. 2009
    ..Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1...
  16. pmc Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection
    Alexander D Douglas
    Jenner Institute, University of Oxford, UK
    J Infect Dis 208:340-5. 2013
    ..We find that the parameters estimated by these models are closely correlated, and their predictive accuracy for omitted data points was similar. We propose that future studies include the linear model...
  17. pmc ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 20:2355-68. 2012
    ..These data call into question the utility of T cell-inducing blood-stage malaria vaccines and suggest that the focus should remain on high-titer antibody induction against susceptible antigen targets...
  18. pmc Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1
    Teresa Lambe
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Sci Rep 3:1443. 2013
    ..These data may be of relevance for the design of optimal immunization regimens for human influenza vaccines, especially for influenza-naïve infants...
  19. pmc Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates
    Alexandra J Spencer
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e33555. 2012
    ..This report demonstrates that antigen multimerization using IMX313 is a simple and effective cross-species method to improve vaccine immunogenicity with potentially broad applicability...
  20. doi request reprint Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines
    Simon J Draper
    Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom
    J Immunol 185:7583-95. 2010
    ..These data encourage the further clinical development and coadministration of protein and viral vector vaccine platforms in an attempt to induce broad cellular and humoral immune responses against blood-stage malaria Ags in humans...
  21. ncbi request reprint Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites
    Philip Bejon
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    J Infect Dis 191:619-26. 2005
    ..Forty-eight-hour growth rates in blood from control subjects were not different from those in blood from any vaccination group (mean, 14.4-fold [95% confidence interval, 11-19-fold])...
  22. pmc Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference
    Emily K Forbes
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    J Immunol 187:3738-50. 2011
    ..These data have important implications for the development of a multistage or multicomponent viral vectored malaria vaccine for use in humans...
  23. pmc Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus
    Amy C Boyd
    The Jenner Institute, Oxford University, Oxford, UK
    Vaccine 31:670-5. 2013
    ....
  24. pmc Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
    Geraldine A O'Hara
    Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, UK
    J Infect Dis 205:772-81. 2012
    ..Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses...
  25. pmc A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine
    David W Porter
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK
    Vaccine 29:7514-22. 2011
    ..There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene...
  26. pmc Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1
    Alexander D Douglas
    Jenner Institute, Oxford University, Oxford, UK
    Vaccine 28:7167-78. 2010
    ....
  27. pmc Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)
    Matthew G Cottingham
    Wellcome Trust Centre for Human Genetics and The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 3:e1638. 2008
    ..Here we demonstrate in proof-of-concept experiments that MVA-BAC recombineering is a viable route to more rapid and efficient generation of new candidate mutant and recombinant vaccines based on a clinically deployable viral vector...
  28. pmc Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses
    Richard D Antrobus
    The Jenner Institute, University of Oxford, Oxford, UK
    Mol Ther 22:233-8. 2014
    ....
  29. pmc Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
    Katie J Ewer
    1 The Jenner Institute Laboratories, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK 2
    Nat Commun 4:2836. 2013
    ..005). Vaccine-induced CD8(+) T cells provide protection against human malaria, suggesting that a major limitation of previous vaccination approaches has been the insufficient magnitude of induced T cells...
  30. ncbi request reprint Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
    ..Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans...
  31. ncbi request reprint Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials
    Laura Andrews
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Am J Trop Med Hyg 73:191-8. 2005
    ..This PCR method has so far been used to follow 137 vaccinee and control volunteers in Phase IIa trials in Oxford and on 220 volunteer samples during a Phase IIb field trial in The Gambia...
  32. ncbi request reprint Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
    Nat Med 10:1240-4. 2004
    ..Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas...
  33. ncbi request reprint Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus
    Richard J Anderson
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 172:3094-100. 2004
    ..berghei and was more immunogenic and protective than DNA/MVA prime/boost immunization. However, further improvement was not achieved by sequential (triple) immunization with a DNA vaccine, FP9, and MVA...
  34. pmc Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial
    Rosalind Rowland
    Jenner Institute University of Oxford, Oxford, UK
    Hum Vaccin Immunother 9:50-62. 2013
    ..We hypothesize that FP85A induced anti-FP9 IgG antibodies with cross-reactivity for MVA85A, which may have mediated inhibition of the immune response to subsequent MVA85A. ClinicalTrials.gov identification number: NCT00653770...
  35. pmc Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density
    Philip Bejon
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, OX3 7LJ, UK
    Malar J 5:104. 2006
    ..Thick blood films are routinely used to diagnose Plasmodium falciparum malaria. Here, they were used to diagnose volunteers exposed to experimental malaria challenge...
  36. pmc Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
    George M Warimwe
    The Jenner Institute, University of Oxford, Oxford, UK
    Virol J 10:349. 2013
    ....
  37. ncbi request reprint Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine
    Caitlin E Mullarkey
    Jenner Institute, Old Road Campus Research Building, Oxford, UK
    Eur J Immunol 43:1940-52. 2013
    ..The simultaneous induction of T cells and Ab responses has the potential to improve seasonal vaccine performance and could be employed in pandemic situations. ..
  38. ncbi request reprint Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
    Shahriar Behboudi
    Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DU, UK
    Vaccine 22:4326-31. 2004
    ..These data indicate that despite the ability of poxviruses to impair DC maturation in vivo, the important ability of MVA to boost CD8 T-cell response in vivo is mediated at the level of the infected dendritic cells...
  39. ncbi request reprint Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance
    Anne C Moore
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, United Kingdom
    J Immunol 175:7264-73. 2005
    ..Vaccine strategies incorporating anti-CD25 lead to improved protection against pre-erythrocytic malaria challenge. These data underpin new strategies for the design and development of more efficacious vaccines in clinical settings...
  40. ncbi request reprint Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome
    Matthew G Cottingham
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK
    J Virol Methods 168:233-6. 2010
    ..These methods greatly facilitate and accelerate production of recombinant MVA, including markerless constructs...
  41. ncbi request reprint Utilizing poxviral vectored vaccines for antibody induction-progress and prospects
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Vaccine 31:4223-30. 2013
    ....
  42. pmc A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years
    Richard D Antrobus
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e48322. 2012
    ..We assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost memory T cell responses, in a group of older adults...
  43. pmc A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity
    Matthew D J Dicks
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e40385. 2012
    ..These findings support the continued development of new chimpanzee adenovirus vectors, including ChAdY25, for clinical use...
  44. pmc Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies
    Patrick J Lillie
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK
    Travel Med Infect Dis 10:192-6. 2012
    ..These data support incorporating travel history into pandemic algorithms...
  45. ncbi request reprint Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors
    Matthew G Cottingham
    The Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK
    Biotechnol Bioeng 109:719-28. 2012
    ..These results have important implications for basic and pre-clinical studies using adenoviral vectors and for derivation of adenoviral vector products destined for large-scale amplification during biomanufacture...
  46. pmc T-cell-inducing vaccines - what's the future
    Sarah C Gilbert
    Jenner Institute, University of Oxford, UK
    Immunology 135:19-26. 2012
    ....
  47. pmc Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909
    Christopher J A Duncan
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e22271. 2011
    ..Here we report the first study to examine the relationship between in vivo Plasmodium falciparum growth rates and in vitro GIA in humans experimentally infected with blood-stage malaria...
  48. pmc Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial
    Fiona M Thompson
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    PLoS ONE 3:e1493. 2008
    ..This trial was the first to combine two existing vaccination strategies to produce a vaccine that induces immune responses to both the pre-erythrocytic and blood stages of the P. falciparum life cycle...
  49. ncbi request reprint Clinical development of Modified Vaccinia virus Ankara vaccines
    Sarah C Gilbert
    Jenner Institute, University of Oxford, ORCRB, OX3 7DQ, UK
    Vaccine 31:4241-6. 2013
    ..The safety of MVA is now well documented, immunogenicity is influenced by the dose and vaccination regimen, and information on the efficacy of MVA-vectored vaccines is now beginning to accumulate...
  50. pmc Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens
    Richard D Antrobus
    The Jenner Institute, University of Oxford, Oxford, UK
    Mol Ther 22:668-74. 2014
    ..We demonstrate ChAdOx1 NP+M1 to be safe and immunogenic. ChAdOx1 is a promising vaccine vector that could be used to deliver vaccine antigens where strong cellular immune responses are required for protection. ..
  51. pmc Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA
    Toritse Orubu
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e40167. 2012
    ....
  52. pmc Incidental diagnosis in healthy clinical trial subjects
    Christopher J A Duncan
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Drive, OX3 7LJ, United Kingdom
    Clin Transl Sci 5:348-50. 2012
    ..02 χ(2) for trend) but not females (p= 0.82). These data will assist those planning and conducting phase I/II vaccine trials in healthy volunteers, and importantly should strengthen the informed consent of future trial participants...
  53. ncbi request reprint Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence
    Caroline L Smith
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX3 9DS, UK
    Int J Cancer 113:259-66. 2005
    ....
  54. pmc A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses
    Eric Prieur
    Weatherall Institute of Molecular Medicine and Cellular Immunology, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Proc Natl Acad Sci U S A 101:290-5. 2004
    ..The use of polyprotein constructs in nonreplicating poxviruses should broaden the target antigen range of vaccine-induced immunity and increase the number of potential epitopes available for immunogenetically diverse human populations...
  55. pmc Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
    Philip Bejon
    Kenya Medical Research Institute, Centre for Geographical Medicine Research Coast, Kilifi, Kenya
    PLoS ONE 2:e707. 2007
    ..5, 95% CI 1.0-2.3). Although the study was unblinded, another nine months follow-up was planned to monitor the incidence of malaria and other serious adverse events...
  56. pmc Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans
    Patrick J Lillie
    Jenner Institute, University of Oxford, UK
    Clin Infect Dis 55:19-25. 2012
    ..Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been conducted in healthy adult volunteers...
  57. pmc Inverse associations of human leukocyte antigen and malaria parasite types in two West African populations
    Karen Young
    Wellcome Trust Centre for Human Genetics, Oxford University, Roosevelt Drive, Oxford OX3 7BN, United Kingdom
    Infect Immun 73:953-5. 2005
    ..e., the malaria parasite, and a major biological mechanism are well defined. We show that this surprising result fits well with the predictions of a mathematical model describing the population genetics and dynamics of this interaction...
  58. pmc Dual neonate vaccine platform against HIV-1 and M. tuberculosis
    Richard Hopkins
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e20067. 2011
    ..tuberculosis infant vaccine platform is established. Induction of immune responses against these pathogens soon after birth is highly desirable and may provide a basis for lifetime protection maintained by boosts later in life...
  59. doi request reprint Advances in the development of universal influenza vaccines
    Sarah C Gilbert
    Jenner Institute, University of Oxford, Oxford, UK
    Influenza Other Respir Viruses 7:750-8. 2013
    ..Several of these have now been taken into clinical development, and this review discusses the progress that has been made, as well as considering the requirements for licensing these new vaccines and how they might be used in the future...
  60. pmc Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area
    Egeruan B Imoukhuede
    Medical Research Council Laboratories, Fajara, The Gambia
    Am J Trop Med Hyg 76:486-93. 2007
    ..These findings support the feasibility and potential of this approach to screen pre-erythrocytic vaccines for efficacy against infection in small numbers of vaccinees in endemic areas...
  61. pmc Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses
    Evans L N Taracha
    International Livestock Research Institute, Nairobi, Kenya
    Infect Immun 71:6906-14. 2003
    ..These data illustrate the general applicability of priming-boosting vaccination strategies for induction of antigen-specific T-cell responses and suggest that the method may be useful for development of veterinary vaccines...
  62. pmc The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum
    Philip Bejon
    Kenya Medical Research Institute, Centre for Geographical Medicine Research Coast Kilifi, Kenya
    J Immunol 179:4193-201. 2007
    ..Malaria may reduce the efficacy vaccinations such as bacillus Calmette-Guérin and investigational T cell-inducing vaccines, and may delay the acquisition of immunity following natural exposure to malaria and other pathogens...
  63. ncbi request reprint Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya
    Philip Bejon
    Kenya Medical Research Institute, Centre for Geographical Medical Research Coast, Kilifi, Kenya
    Clin Infect Dis 42:1102-10. 2006
    ....
  64. pmc Characterization of the fine specificity of bovine CD8 T-cell responses to defined antigens from the protozoan parasite Theileria parva
    Simon P Graham
    International Livestock Research Institute, PO Box 30709, Nairobi 00100, Kenya
    Infect Immun 76:685-94. 2008
    ..These data demonstrate that the identified antigens are inherently dominant in animals with the corresponding MHC genotypes...
  65. pmc Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals
    Philip Bejon
    Kenya Medical Research Institute, Centre for Geographical Medical Research Coast, P O Box 230, Kilifi, Kenya
    Infect Immun 74:6331-8. 2006
    ..This demonstrated that double-cytokine-producing cells were highly predictive of memory. This assay may be useful in predicting vaccinations most likely to generate stable, long-term memory responses...
  66. ncbi request reprint Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area
    Philip Bejon
    Kenya Medical Research Institute, Centre for Geographical Medical Research Coast, Kilifi, Kenya
    Eur J Immunol 36:2264-72. 2006
    ..Vaccines administered by heterologous prime-boost regimes are being developed for diverse pathogens and cancer. These data suggest these vaccines should also be administered by alternating vector regimens in clinical development...
  67. pmc A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis
    Tim J Bull
    Department of Cardiovascular Sciences Surgery, St George s University of London, London, United Kingdom
    PLoS ONE 2:e1229. 2007
    ..Hitherto, the only vaccines available against Mycobacterium avium subspecies paratuberculosis have been limited to veterinary use and comprised attenuated or killed organisms...
  68. ncbi request reprint Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area
    Philip Bejon
    Kenya Medical Research Institute, Centre for Geographical Medical Research, Coast, Kenya
    Vaccine 24:4709-15. 2006
    ..The potential for enhanced immunogenicity with half doses of priming vectors warrants further investigation, and larger studies to determine protection against malaria in children are required...
  69. ncbi request reprint Competition between CTL narrows the immune response induced by prime-boost vaccination protocols
    Michael J Palmowski
    Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 168:4391-8. 2002
    ..Our findings define a novel vaccination strategy optimized for the induction of an effective polyvalent cytotoxic response...
  70. pmc A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, Gambia
    PLoS Med 1:e33. 2004
    ....
  71. pmc Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin
    H Martin Vordermeier
    TB Research Group, Veterinary Laboratories Agency Weybridge, New Haw, Addlestone, Surrey, UK
    Immunology 112:461-70. 2004
    ....
  72. ncbi request reprint Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection
    Michael Walther
    Center for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
    Immunity 23:287-96. 2005
    ..P. falciparum-mediated induction of regulatory T cells may represent a parasite-specific virulence factor...
  73. ncbi request reprint Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria
    Sheila M Keating
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, Churchill Hospital, Oxford, United Kingdom
    J Immunol 175:5675-80. 2005
    ..This cultured assay identifies long-lasting protective T cell responses and therefore offers an attractive option for assessments of vaccine immunogenicity...
  74. ncbi request reprint Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, Gambia
    J Infect Dis 189:2213-9. 2004
    ..These results highlight optimized combination regimens with general relevance to the development of vaccines targeting intracellular pathogens...
  75. pmc Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria
    Nathan W Schmidt
    Department of Microbiology, University of Iowa, Iowa City, IA 52242, USA
    Proc Natl Acad Sci U S A 105:14017-22. 2008
    ..Furthermore, the extremely large threshold in memory CD8 T cell frequencies required for long-term protection in mice may have important implications for development of effective malaria vaccines...
  76. pmc Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein
    Michael Walther
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, United Kingdom
    Infect Immun 74:2706-16. 2006
    ..Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge...
  77. ncbi request reprint Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes
    Michael Walther
    Center for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, Churchill Hospital, Oxford, United Kingdom
    J Immunol 177:5736-45. 2006
    ..Furthermore, the in vitro observations on cytokine kinetics presented here, suggest that intact schizont-stage infected RBC can trigger innate responses before rupture of the infected RBC...
  78. pmc Progression of Plasmodium berghei through Anopheles stephensi is density-dependent
    Robert E Sinden
    Division of Cell and Molecular Biology, Faculty of Life Sciences, Imperial College London, London, United Kingdom
    PLoS Pathog 3:e195. 2007
    ....
  79. pmc Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes
    Simon P Graham
    International Livestock Research Institute, Nairobi, Kenya
    Proc Natl Acad Sci U S A 103:3286-91. 2006
    ..These data provide a basis for developing a CTL-targeted anti-East Coast fever subunit vaccine. In addition, orthologs of these antigens may be vaccine targets for other apicomplexan parasites...